Die konservative Alternative zu Caprius - UROCOR!!! - 500 Beiträge pro Seite

[Doc Bio]

Hallo zusammen

Die letzten Tage habe ich ein bisschen Urlaub gemacht und mich intensiv mit Werten aus dem Medizin- und Biotechnologiebereich beschäftigt. Aus ungefähr 150 Werten (alle Nasdaq oder OTC USA) habe ich fünf Werte herausgefiltert, die ich für besonders aussichtsreich halte:

Im Wochenabstand werde ich die einzelnen Werte vorstellen, da ich zeitlich nicht mehr schaffe. Ob alle so performen wie Caprius weiss ich nicht, jedoch sind alle deutlich unterbewertet und haben 500 - 1000% Potential auf Jahressicht. Bewusst habe ich Werte ausgesucht, welche deutlich konservativer wie Caprius sind und nicht diesen spekulativen Charakter haben, um auch unerfahrenen Anleger Investmentalternativen bieten zu können .

Heute nun als erste Empfehlung UROCOR (UROC), in D unter der WK: 900847 in Berlin gehandelt. Aber Käufe, wenn möglich in USA abwickeln - liquider Handel ist hier gewährleistet. Das Potential sehe ich bei Urocor bis 20-25 $ da Buchwert von 1.2 und solide Umsätze Quartal für Quartal generiert werden. Die Homepage ist sehr informativ und gibt auf viele Fragen eine Antwort!

Kurz eine Darstellung des Geschäftsgebietes von UROC und des Managements, welches aus echten High Potentials besteht:


UroCor provides solutions for the clinical management of prostate, bladder, and kidney stone diseases. UroCor`s products and services complement critical decision-making processes throughout the detection, diagnosis, prognosis, monitoring, and therapy phases of a patient`s disease cycle.

UroCor`s four business groups, UroDiagnostics, UroSciences, UroTherapeutics, and Disease Management Information Systems, develop innovative integrated disease management approaches to serve the needs of patients, urologists, and managed care organizations. The incorporation of research and development, diagnostic services, therapeutic products, and information services makes UroCor the leader in urological Total Disease Management.





Chairman of the Board and Chief Executive Officer
Mr. Hagstrom has been a director of UroCor and served as President and Chief Executive Officer of UroCor from November 1989 to September 1998. In September 1998, Michael George was appointed Chief Operating Officer and assumed the role of President. Mr. Hagstrom was appointed Chairman of the Board of Directors in September 1994. Before joining UroCor, Mr. Hagstrom was Vice President of the Scientific Products Division of Baxter-Travenol, a medical products company, where he served in various marketing, sales, product planning and general management positions from November 1985 to November 1989. Prior to joining Baxter-Travenol, he spent three years at American Hospital Supply Corporation until it was acquired by Baxter-Travenol and three years at Becton Dickinson & Company in various management positions.






President and Chief Operating Officer
Mr. George joined UroCor in August 1998 as President and Chief Operating Officer. Prior to joining UroCor, Mr. George served as both President International and President North America with DuPont Merck Pharmaceuticals, during which time the firm`s annual revenue grew from $400 million to $1.4 billion over an eight-year period. With more than 25 years experience in the pharmaceutical industry, his background includes senior sales, marketing and general management positions with DuPont Merck, Bristol Myers and Sandoz.






Senior Vice President, Corporate Planning and Development, Assistant Secretary
Mr. Choumbakos was promoted to Senior Vice President, Corporate Planning and Development in May 1997. He joined UroCor in June 1992 as Vice President, Corporate Development and Chief Financial Officer and Secretary. Before joining UroCor, Mr. Choumbakos was President of Venture Development Group, a corporate and business development consulting firm, from March 1988 to June 1992. From March 1988 to December 1990, Mr. Choumbakos was also Vice President and Chief Financial Officer of Creative Business Strategies, Inc., a business development consulting firm. From August 1979 to March 1988, Mr. Choumbakos was Director of Corporate Development at Becton Dickinson & Co., a medical products company. Prior to 1979, he was a Senior Manager with Price Waterhouse & Co. where he worked for 13 years.






Vice President, New Product and Business Development
Mr. Dimitroff joined UroCor in April 1990 as Vice President, Marketing and Sales and became Vice President and General Manager UroDiagnostics Group in October 1994. Before joining UroCor, Mr. Dimitroff served as Vice President, Marketing and Sales for Dianon Systems, Inc., an oncology specialty reference laboratory, from 1984 to April 1990. Prior to 1984, he held senior marketing and sales management positions with MetPath, Inc., a large general reference laboratory, and American Hospital Supply Corporation.





Vice President and General Manager, UroSciences Group
Dr. Veltri joined UroCor in October 1990 as Vice President, Product Planning and Technology Development and Chief Scientific Officer, and became Vice President and General Manager, UroSciences Group in October 1994. In 1994, Dr. Veltri was appointed adjunct professor of pathology at the Oklahoma University Sciences Health Sciences Center. Before joining UroCor, Dr. Veltri was the Executive Vice President and Chief Technical Officer at Theracel, Inc., a small molecule therapeutics development company in Rockville, MD, from 1988 to October 1990. From 1984 to 1988, Dr. Veltri was a founder and President and Chief Executive Officer of American Biotechnology Company, the predecessor to Theracel, Inc. Prior to 1984, Dr. Veltri was Director of Research and Development for the Immunology Group (rapid in vitro diagnostic test development) at Cooper Biomedical Inc., a diagnostic products company located in Malvern, PA. From 1968-81, he was Professor of Microbiology and Surgery, Director of Research in Otolaryngology and Supervisor of the Special Immunology and Virology Clinical Pathology Laboratory at West Virginia University Medical School.






Senior Vice President, Chief Financial Officer, Secretary, Treasurer
Mr. Hayden joined UroCor in April 1999 as Senior Vice President, Chief Financial Officer, Secretary and Treasurer. Before joining the Company, Mr. Hayden was Executive Vice President, Financial Operations of Medshares, Inc., a privately held home healthcare management company from July 1994 to December 1998, except for a majority of 1996 (February through August), when he served as Group Chief Financial Officer for Columbia Homecare Group, a home healthcare company. From September 1992 to June 1994, he held the position of Chief Internal Audit Director with First American Homecare, also a home healthcare company. Prior to moving into the private healthcare industry, Mr. Hayden served in various Audit Manager positions with the public accounting firms of BDO Seidman and Adams & Akin, PC for nine years.






Vice President, Sales and General Manager, UroTherapeutics Group
Mr. Nigg was promoted to Vice President and General Manager of UroTherapeutics in September, 1998 after joining the company in February 1998 as Vice President, UroTherapeutics Business Development. Prior to UroCor, Mr. Nigg had senior management responsibilities for operations, marketing, sales and sourcing for Amersham Healthcare, a pharmaceutical, medical equipment and consumer health care products company. Mr. Nigg was Amersham`s Vice President of Sales/ Pharmacy Operations covering 26 states from October 1993 until January 1998.






Vice President, Chief Compliance Officer
Ms. Carmichael was promoted to Vice President, Sales & Client Relations in September, 1998. First joining UroCor in April, 1990 as Manager of Telemarketing, she was promoted to Marketing Manager in April, 1992, and Director of Human Resources in 1995. In September 1996, Ms. Carmichael was named Director of Sales and Client Relations and held this position until she assumed her current role in February, 1998. Prior to joining UroCor, Ms.Carmichael held various sales and marketing management positions with Eveready Battery Company, a wholly owned subsidiary of Ralston Purina.


Bis demnächst

Doc Bio

[Doc Bio]

Sorry, das kürzel in USA ist UCOR!!!


Doc Bio

[prayer]

Hey Doc,

danke für Deine Mühe, ich suche noch ein/zwei Biotecaktien und bin für jede Info dankbar!!!

mike

[Doc Bio]

Hi prayer

Habe selbst auch BB biotech, aber möchte gerne meinen eigenen Bio-Medizintechnikfonds mit 5 - 10 Werten aufbauen. Investition pro position so ungefähr 10.000 DM.

Vielleicht kann ich BB Biotech schlagen, allerdings haben es die Jungs echt drauf. Bin gespannt, wer die bessere Jahresperformance einfahren wird.

2000 wird das Jahr der bio- und Medizinwerte, da bin ich mir ganz sicher. Die Perlen hier befinden sich in USA, da die Werte am Neuen Markt einfach jenseits von gut und böse bewertet sind.


Doc Bio

[Doc Bio]

Kurz noch ein paar Daten vom Yahoo-Board, denke die Kennziffern sprechen für sich:


Recent Events
Jan 11 Price hit new 52-week high ($8.313)
Location
840 Research Parkway
Oklahoma City, OK 73104
Phone: [phone]
Fax: [phone]
Email: [e-mail]
Employees as of 12/98: 310
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Journal Archive
 ·Raw SEC Filings
Competitors:
 ·Sector: Healthcare
 ·Industry: Healthcare Facilities
Company Websites
 ·Home Page
 ·Investor Relations
 ·Yahoo! Category
 ·Search Yahoo! for related links...

Ownership
· Insider: 44%
· Over the last 6 months:
 · one insider sell; 20.0K shares
  (0.5% of insider shares)
· Institutional: 56% (99% of float)
(42 institutions)
· Net Inst. Buying: 183.0K shares (+3.42%)
(prior quarter to latest quarter)

Business Summary
UroCor Inc. markets a comprehensive range of integrated products and services to assist in detecting, diagnosing, treating and managing prostate cancer, bladder cancer, kidney stones and other complex urologic disorders directly to urologists and managed care organizations. UroCor`s primary focus is helping urologists improve patient care and outcomes, while reducing the total cost of managing these diseases. The Company currently conducts its business through the following segments: UroDiagnostics Group, UroTherapeutics Group, UroSciences, and Disease Management Information Systems Group.
Financial Summary
UCOR provides diagnostic services for the clinical management of certain urological cancers and diseases, and provides information services and therapeutic products to urologists and HMOs. For the nine months ended 9/99, revenues rose 3% to $34.6 million. Net loss rose 9% to $4.1 million. Revenues reflect increased case volume. Higher losses reflect increased SG&A expenses due to additional management personnel, increased professional fees and depreciation costs.
Officers [Insider Trade Data]

FY1998 Pay

--------------------------------------------------------------------------------

William Hagstrom, 41
Chairman $254K
Michael George, 50
Pres, CEO, Chief Operating Officer, Director 157K
Bruce Hayden, 38
Sr. VP, CFO, Sec. and Treasurer --  
Socrates Choumbakos, 54
Sr. VP, Corp. Planning and Devel. and Assistant Sec. 166K
Mark Dimitroff, 52
VP, New Product and Bus. Devel. 168K
Dollar amounts are as of 31-Dec-1998 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..



--------------------------------------------------------------------------------
More from Market Guide: Highlights -Performance - Ratio Comparisons


Statistics at a Glance -- NasdaqNM:UCOR As of 11-Feb-2000
Price and Volume
52-Week Low
on 28-Oct-1999 $2.75 
Recent Price $4.75 
52-Week High
on 11-Jan-2000 $8.313
Beta 0.79 
Daily Volume (3-month avg) 61.6K
Daily Volume (10-day avg) 53.0K
Stock Performance

big chart [1d | 5d | 3mo | 1yr | 2yr | 5yr]
52-Week Change -15.6%
52-Week Change
relative to S&P500 -25.1%
Share-Related Items
Market Capitalization $43.8M
Shares Outstanding 9.23M
Float 5.20M
Dividends & Splits
Annual Dividend none 
Last Split none 
Per-Share Data
Book Value (mrq) $4.11 
Earnings (ttm) -$0.29 
Earnings (mrq) $0.01 
Sales (ttm) $4.65 
Cash (mrq) $1.34 
Valuation Ratios
Price/Book (mrq) 1.16 
Price/Earnings N/A 
Price/Sales (ttm) 1.02 
Income Statements
Sales (ttm) $48.5M
EBITDA (ttm) -$2.32M
Income available to common (ttm) -$2.81M
Profitability
Profit Margin (ttm) -5.8%
Operating Margin (ttm) -10.5%
Fiscal Year
Fiscal Year Ends Dec 31
Most recent quarter 30-Sep-1999
Management Effectiveness
Return on Assets (ttm) -5.67%
Return on Equity (ttm) -6.22%
Financial Strength
Current Ratio (mrq) 6.90 
Debt/Equity (mrq) 0.00 
Total Cash (mrq) $14.8M
Short Interest
As of 10-Jan-2000
Shares Short 33.0K
Percent of Float 0.6%
Shares Short
(Prior Month) 8,000 
Short Ratio 0.40 
Daily Volume 82.0K

See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-Sep-1999)

Bis morgen

Doc Bio

[Doc Bio]

Bei Urocor muss man Geduld haben, aber dann winken saftige Kursgewinne, denn meiner Ansicht nach ist Urocor als 30%iger Marktführer in USA noch gar nicht bekannt.

Werde versuchen Fondsmanager auf diesen Wert anzusprechen???

Neueste Meldung: Home - Yahoo! - Help

-------------------------------------------------------------------------------
Related Quotes

UCOR
5 1/8
+3/8


Thursday February 17, 8:31 am Eastern Time
Company Press Release
SOURCE: UroCor, Inc.
UroCor Begins Shipment of ProstaSeed(TM) I-125 Sources For Radiation Treatment Of Prostate Cancer
Launch Into Therapeutic Arena Illustrates Company`s Intent to be Involved With Range of Urological Products for Diagnosis, Prognosis and Treatment
OKLAHOMA CITY, Feb. 17 /PRNewswire/ -- Recently published medical studies have drawn attention to the complexities of treating prostate cancer in men, including which therapy to use for combating the cancer itself as well as for avoiding unwanted post-treatment side effects, such as impotence and incontinence. The reports also help illustrate how UroCor, Inc., (Nasdaq: UCOR - news), has positioned itself as the singular healthcare company involved in all phases of urological patient diagnosis and treatment:


-- UroCor`s screening tests such as those for prostate specific antigen
(PSA) are used by up to one-third of the nation`s urologists to detect
prostate cancer;

-- UroCor`s sophisticated prognostic tests such as sextant biopsies help
specialists determine whether surgery or radiation therapy is the
preferred treatment;

-- And this week, UroCor began shipping to U.S. radiation oncologists its
ProstaSeed(TM) I-125 sources, cleared last month for radiation
treatment of prostate cancer.


``The ProstaSeed launch for the first time places UroCor squarely in the middle of prostate cancer treatment following years of being a leader in laboratory testing,`` said Michael George, President and CEO of UroCor. ``And we are continuing to develop our offerings in other areas. For example, our Persist(TM) biofeedback kit to treat incontinence is getting renewed marketing attention among post-surgery patients, while a new, proprietary testing method developed with Johns Hopkins shows promise in determining how up to 80% of post-surgical patients should be treated in regard to recurrence of their cancer.``

An article in the January 21 edition of the Journal of the American Medical Association (JAMA) said that 60% of men followed in a major study conducted in six states reported being impotent within 18 months following removal of their cancerous prostates and that 8% suffered urinary incontinence.

``Studies such as the one in JAMA have drawn increased medical attention as to how to better qualify which patients should have surgery and which might be better served with radiation treatment,`` George continued. ``Additionally, research is continuing to determine by laboratory testing which post-surgical patients are likely to have a recurrence of cancer and what type of treatment may be needed. Finally, both the medical community and patients are talking more openly about unwanted side effects, such as incontinence, and what patients can do about it. UroCor is active in all these areas.``

To more quickly penetrate the market for a primary radiation treatment called brachytherapy -- where sources or ``seeds`` are implanted in the prostrate -- UroCor has previously entered into marketing and distribution agreements with Mallinckrodt Inc. and with Prostate Services of America (PSA). Mallinckrodt operates 35 nuclear pharmacies and services 80 independent pharmacies. PSA is a major marketer of premium medical equipment and services for prostate therapy. The ProstaSeed sources are manufactured by Mills Biopharmaceuticals, also of Oklahoma City, on an exclusive basis for UroCor.

Approximately 200,000 new cases of prostate cancer are diagnosed in the U.S. each year, and about 60% of these are potentially treatable with brachytherapy. Market size is in the range of $150 million to $180 million for prostate therapy alone with the future potentiality of brachytherapy for other organs as well. UroCor is the only medical company involved in prostate cancer treatment that has the ability to support both the urologist and the radiation oncologist in diagnosing and managing the patient.

George said UroCor`s next new therapeutic product is expected to be PACIS(TM) BCG for treatment of bladder cancer. PACIS is being licensed in the U.S. from BioChem Pharma and is still awaiting FDA regulatory clearance.

An article in the November 1999 issue of Urology magazine detailed the studies at UroCor and The Johns Hopkins Hospital which found better tests to predict which men in the ``intermediate risk of progression`` category following prostate surgery -- about 80% of all patients -- would most likely have a recurrence of cancer. These tests have not yet been approved for general usage.

About UroCor

UroCor markets a comprehensive range of integrated products and services to assist in detecting, diagnosing, treating and managing prostate cancer, bladder cancer, kidney stones and other complex urologic disorders directly to Urologists and managed care organizations. The Company`s primary focus is helping Urologists improve patient care and outcomes while reducing the total cost of managing these diseases. The Company presently serves over one-third of the office-based Urologists in the United States, many of them over its Internet-based wide area network.

Safe Harbor Statement

Statements in this news release that are not strictly historical, including statements as to plans, objectives and future financial performance, are ``forward-looking`` statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Although UroCor believes that the expectations reflected in such forward- looking statements are reasonable, it can give no assurance that the expectations will prove to be correct. Factors that could cause actual results to differ materially from UroCor`s expectations include, among others, competition within the healthcare and medical services industries; the effects of government regulation and reimbursement policies on the healthcare market and the Company, including the possibility of being deemed not to be in compliance with federal or state regulatory requirements; the Company`s access to and the market`s acceptance of new diagnostic and therapeutic products; the Company`s ability to market and distribute diagnostic and therapeutic products profitably; the Company`s ability to maintain or expand contractual relationships with managed care organizations; the Company`s ability to acquire or develop and implement appropriate management information systems; as well as the risks, uncertainties and other factors described from time to time in the Company`s periodic filings with the Securities and Exchange Commission.

For more information about UroCor toll-free via fax, dial 1-800-PRO-INFO or 1-800-776-4636, follow the voice menu prompts and enter the company code UCOR or 8267 on any touch tone phone, or visit the UroCor page on the FRB website at www.frbinc.com Visit the UroCor website at www.urocor.com

SOURCE: UroCor, Inc.

DocBio

[stockraser]

Doc: deine beiträge sind sehr interessant, ich bräue jetzt, dass ich nach einer woche nicht mehr an caprius geglaubt habe und sie zu ,38 verschenkt habe. War ein guter Tip, danke.

kann ich bei urocor mit was ähnlichem rechnen, und was war der haken wo sie mal kurz bei 7 stand????

viele grüße und vielen Dank

stockraser

[Doc Bio]

Hi stockraser

Habe meinen Einsatz bei CAPR auch rausgezogen, den idealen Ausstiegszeitpunkt findet man nie. Hauptsache Gewinn gemacht!
Doch Urocor ist deutlich weniger spekulativ als Caprius und hat langfristig ein deutlich höheres Potential, denn das Management ist interessiert an höheren Kursen um Spezialwertefonds wieder auf den Titel aufmerksam zu machen. Ich denke, dass der ausbruch kurz bevor steht, doch jemand versucht den Kurs unten zu halten. Doch dafür wird der anstieg um so heftiger ausfallen!!!

DocBio

[Doc Bio]

Hi

Urocor schwankt heute heftig, aber mit Umsätzen wird der Kurs weiter steigen, denn die Unterbewertung wird abgebaut werden.
Heute schon 7,5 $!!!


Doc

[Doc Bio]

Hallo zusammen

Schaut euch mal den Chart an!!!
Es kann sich nur noch um Tage halten, bis der Ausbruch kommt - leider noch kein Umsatz in Deutschland.

Mich beeindruckt vor allem das hervorragende Management und der hohe Cashbestand!

Urocor ist ein klarer Kauf, aber wer nicht will, der solls lassen.

DocBio